Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.
Surmodics, Inc. (SRDX) generates news as a provider of medical device technologies, vascular intervention devices, and in vitro diagnostic components. Company announcements frequently highlight developments in its performance coating technologies for intravascular devices, its Pounce™ Thrombectomy Platform, and its SurVeil™ drug-coated balloon (DCB), as well as financial results and corporate transactions.
Investors and industry observers following Surmodics news can expect updates on clinical and real-world evidence for its vascular intervention products. The company has reported data from the PROWL registry, an open-label, multi-center U.S. registry evaluating the Pounce Thrombectomy Platform for non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. News coverage includes analyses of 160-patient cohorts with symptomatic limb ischemia and sex-specific outcomes, presented at conferences such as the VIVA Vascular Symposium and the TCT Symposium.
Surmodics also issues press releases on product milestones, including the commercial release and early clinical use of the Pounce XL Thrombectomy System, which is intended for thrombus and embolus removal in peripheral arteries of larger diameters. Additional news has covered publication of the TRANSCEND clinical trial, which evaluated the SurVeil DCB in femoropopliteal arterial disease.
Financial news from Surmodics includes quarterly earnings releases, segment revenue trends in its Medical Device and In Vitro Diagnostics businesses, and updates to fiscal year guidance. The company has also reported on a pending and subsequently completed acquisition by an affiliate of GTCR LLC, including regulatory actions, court decisions related to the Federal Trade Commission’s attempt to block the transaction, and steps toward delisting from Nasdaq and transitioning to private ownership.
By monitoring this news feed, readers can track Surmodics’ product performance data, regulatory and legal developments, and financial disclosures as the company advances its mission to improve the detection and treatment of disease.
Surmodics, Inc. (Nasdaq: SRDX) will host a live webcast of its Q1 fiscal 2021 conference call on February 9, at 7:30 a.m. CT. An earnings news release will precede the call. Key executives including CEO Gary Maharaj and CFO Tim Arens will discuss financial results and accomplishments. The webcast can be accessed via the investor relations section of the company’s website. An audio replay will be available from February 9 to February 16. Surmodics specializes in surface modification technologies for medical devices and aims to address unmet clinical needs.
Surmodics, Inc. (NASDAQ:SRDX) announced the presentation of 12-month data from its TRANSCEND clinical trial at the Leipzig Interventional Course 2021. This trial compared the efficacy and safety of the SurVeil™ drug-coated balloon (DCB) against the IN.PACT® Admiral® DCB in patients with femoropopliteal artery disease. Results showed that SurVeil DCB is non-inferior to the higher drug dose IN.PACT Admiral while using a substantially lower paclitaxel dose. The SurVeil DCB exhibited a primary patency rate of 81.7% and a strong safety profile, suggesting it may set a new standard in PAD treatment.
Surmodics, Inc. (NASDAQ:SRDX) has announced the presentation of 12-month data from its TRANSCEND clinical trial at the Leipzig Interventional Course (LINC) 2021 virtual event on January 25, 2021. Dr. Kenneth Rosenfield will present findings comparing the SurVeil drug-coated balloon with the IN.PACT Admiral drug-coated balloon for treating femoropopliteal artery disease. The trial evaluated the safety and efficacy of the SurVeil device, involving 446 patients across 65 sites, focusing on primary patency and safety endpoints.
Surmodics, Inc. (NASDAQ:SRDX) presented 6-month data from its AVESS first-in-human study of the Avess™ AV Fistula drug-coated balloon (DCB) at the Vascular Interventional Advances (VIVA) 2020 virtual conference. The study indicated a target lesion patency of 90.9% at 6 months and no reported adverse events. The Avess DCB, designed to minimize paclitaxel exposure, aims to enhance vascular treatment by improving drug distribution within arteries. Data was collected from 12 patients, emphasizing the device's safety and potential benefits in vascular access management.
Surmodics, Inc. (Nasdaq: SRDX) reported fourth quarter fiscal 2020 revenue of $22.5 million, down 27% year-over-year. The company experienced a GAAP loss per share of ($0.22), compared to earnings of $0.26 in the prior year. Medical Device revenue declined 31% to $17.2 million, influenced by $1.6 million from a deal with Abbott Vascular. In Vitro Diagnostics revenue was $5.4 million, a 10% decrease. Cash and short-term investments stood at $61.1 million with no debt. The company has refrained from providing future guidance due to COVID-19 uncertainties.
Surmodics, Inc. (Nasdaq: SRDX) will host a live webcast on November 4, 2020, at 4 p.m. CT to discuss its fourth quarter fiscal 2020 results. The earnings release will be issued post-market close that day. CEO Gary Maharaj and CFO Tim Arens will detail financial results and accomplishments during the call. An audio replay will be available from 7 p.m. CT on November 4 until 7 p.m. CT on November 11. Surmodics specializes in surface modification technologies for medical devices and chemical components for in vitro diagnostic tests.